BullishMEDIUM severityEarnings7d ago

Protalix BioTherapeutics beats top-line and bottom-line estimates; reaffirms FY26 outlook

Protalix BioTherapeutics beats top-line and bottom-line estimates; reaffirms FY26 outlook — $PLX one-month chart
$PLX daily closes over the past month · Wook of Wall Street artwork from market data

At a glance

WOOKAI ASSISTANTREADY
WOOK AIASK ANYTHING · NEVER ADVISES

Ask about PLX. Get explanations, comparisons and calculations with the source lookups shown.

Risk check · protalix biotherapeuticsEvent risk Low

Nothing reported about protalix biotherapeutics across key-person, legal, regulatory, security, operational or financial-integrity risk in three weeks of coverage and 30 days of SEC filings.

From here · last month’s volatility 67% a year
Now $2.93Week $2.66–$3.21 (±9.4%)Month $2.37–$3.50 (±19.2%)
Ask Wook AI

Ranges are one standard deviation of volatility around the latest close — about 1 week in 3 moves further. Not a forecast or investment advice.

Wook analysis

What it means

Key points
  • What to watch: Good results are the headline, guidance is the sequel — and markets usually care more about the sequel.
  • How the stock is trading: $PLX -3.14% in the latest session.
  • Timing: It was published before the opening bell, so the next session was the first chance to trade on it.

Where the stock stands

Protalix BioTherapeutics ($PLX) fell 3.14% to $2.94 in the latest session. Over the past month it is up 14.6%. That leaves it 8.0% below its 52-week high of $3.19 and 78% above its low of $1.65. The high sits 93% above the low, a wide range for one year.

What the filings say

In its latest report (10-Q, filed Nov 10, 2026), $PLX earned $4.0M over the quarter to Sep 30, 2026 on revenue of $21.9M (+10.2% QoQ). Operations brought in $15.5M of cash over the nine months to Sep 30, 2026; after capital spending, free cash flow was $13.4M. Total liabilities were $37.7M against $22.0M of cash on Sep 30, 2026. The company filed an 8-K — the form for material events — on Nov 10, the same day as this story; it is $PLX's own account and the first thing to read. Figures are as filed with the SEC; the $PLX page has the full statements.

How much coverage it is getting

This is the only story on Protalix BioTherapeutics in Wook's last 30 days of coverage, so there is no recent run to compare it with.

The bigger picture

Earnings stories turn less on the headline numbers than on how they compare with what analysts expected, and on guidance for next quarter. A beat with weak guidance can land worse than a miss with a raised outlook — markets grade on the curve. Wook's supply-chain scanner shows no unusual stress in Health Care today.

What to watch next

For the company's side of it, read its latest SEC filings on the $PLX page. A US company has to report material news on an 8-K, usually within four business days; foreign issuers use a 6-K. Where several outlets agree is usually the news; where they differ is the angle. Wook AI, at the top of the page, can work out how far $PLX is from its high or compare this week's coverage with earlier weeks.

Discussion

No one has weighed in yet. Start the discussion on this story.

What happened after this published

Seeking Alpha published this on November 10, 2026. $PLX has moved +11.43% ($2.63 to $2.94). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.

Headline and link are attributed to Seeking Alpha. Wook of Wall Street is an independent research tool and is not affiliated with Seeking Alpha. Nothing here is financial advice or a recommendation — research and educational content only.

Choose what Wook may measure. Essential sign-in and security cookies stay on.

Read the privacy policy